A regulatory perspective on missing data in the aftermath of the NRC report

Statistics in Medicine

Volumn 35, Issue 17, 2016, Pages 2853-2864

  LaVange, Lisa M ^a   Permutt, Thomas ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

clinical trials: design; conduct; drug regulation; missing data

Indexed keywords

HEMOGLOBIN A1C; INSULIN; MANNITOL; PLACEBO; VILANTEROL;

ANALYSIS OF COVARIANCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DATA ANALYSIS; DECISION MAKING; DISEASE COURSE; DRUG CONTROL; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HUMAN; INFORMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTENTION TO TREAT ANALYSIS; MATHEMATICAL ANALYSIS; MEDICAL SOCIETY; MISSING DATA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PARAMETRIC TEST; PREVENTION STUDY; PROCESS OPTIMIZATION; PROTOCOL COMPLIANCE; QUALITY OF LIFE; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STUDY DESIGN;

EID: 84977529901     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6840     Document Type: Article

References (28)

1. National Research Council of the National Academies. The Prevention and Treatment of Missing Data in Clinical Trials. National Academies Press: Washington, D.C., 2010.
2. Ware JH, Harrington D, Hunter DJ, D'Agostino RB Sr. Missing data. New England Journal of Medicine 2012; 367(14):1353–1354.
3. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, Hogan JW, Molenberghs G, Murphy SA, Rotnitsky A, Scharfstein D, Neaton JD, Shih W, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. New England Journal of Medicine 2012; 367(14):1355–1360.
4. Little RJ, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Neaton JD, Shih W, Siegel JP, Stern H. The design and conduct of clinical trials to limit missing data. Statistics in Medicine 2012; 31(28):3433–3443.
5. Permutt T for the Missing Data Working Group. A taxonomy of estimands for regulatory clinical trials with discontinuation. Availabe at: https://www.amstat.org/meetings/jsm/2014/onlineprogram/AbstractDetails.cfm?abstractid=312996.
6. Permutt T for the Missing Data Working Group. Sensitivity analysis for missing data in regulatory submissions. Statistics in Medicine 2015. DOI: 10.1002/sim.6753.
7. Tsiatis A. Semiparametric Theory and Missing Data. Springer: New York, 2006.
8. Tsiatis AA, Davidian M, Zhang M, Lu X. Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Statistics in Medicine special issue on “Statistical methods in HIV/AIDs and its practical application.” 2008; 27:4658–4677.
9. LaVange LM, Durham TD, Koch GG. Randomization-based nonparametric analysis of multicentre trials. Statistical Issues in Medical Research 2005; 14:1–21.
10. nd Edition. John Wiley & Sons: Chichester, 2007; Chapter 3: 27–41.
11. Fisher LD, Dixon DO, Herson J, Frankowski RK, Hearron MS, Peace KE. Intention to treat in clinical trials. In Statistical Issues in Drug Research and Development, Peace KE (ed). Marcel Dekker: New York, 1990; 331–350.
12. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information Journal 1991; 25:411–424.
13. Koch GG, Davis SM, Anderson RL. Methodological advances and plans for improving regulatory success for confirmatory studies. Statistics in Medicine 1998; 17:1675–1690.
14. O'Neill RT, Temple R. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clinical Pharmacology & Therapeutics 2012; 91(3):550–554.
15. CDER Guidance for Industry: Complicated Urinary Tract Infections: Developing Drugs for Treatment. Food and Drug Administration website. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070981.pdf. Accessed August 22, 2014.
16. Cystic Fibrosis Foundation Therapeutics Development Network website. http://www.cff.org/research/tdn. Accessed August 22, 2014. Updated February 4, 2014.
17. Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW. Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax 2012; 67:882–890.
18. Statistical Review, Drug Approval Package, Kalydeco (ivacaftor) 150 mg tablets. Food and Drug Administration website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203188s000TOC.cfm. Accessed August 25, 2014.
19. Khin NA, Chen Y-F, Yang Y, Yang P, Laughren TP. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. Journal of Clinical Psychiatry 2012; 73(6):856–864.
20. Davis SM, Koch GG, Davis CE, LaVange LM. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the CATIE studies. Schizophrenia Bulletin 2003; 29(2):73–80.
21. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005; 353:1209–1223.
22. Browne LH, Graham PH. Good intentions and ICH-GCP: Trial conduct training needs to go beyond the ICH-GCP document and include the intention-to-treat principle. Clinical Trials 2014; 11(6): 629–634.
23. Meeting materials for the January 30, 2013 Meeting of the Pulmonary-Allergy Drugs Advisory Committee Meeting. Food and Drug Administration website. (http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ucm338461.htm). Updated February 6, 2013. Accessed September 5, 2013.
24. Meeting materials for the September 10, 2013 Meeting of the Pulmonary-Allergy Drugs Advisory Committee. Food and Drug Administration website. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/ucm367409.htm. Updated September 6, 2013. Accessed September 8, 2013.
25. O'Kelly MO, Ratitch B. Clinical Trials with Missing Data 2014. John Wiley & Sons: Chichester, West Sussex, UK.
26. Meeting materials for the April 1, 2014 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. Food and Drug Administration website. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm386727.htm. Updated March 24, 2014. Accessed August 1, 2014.
27. Koch GG. Comments on ‘Current issues in non-inferiority trials.’. Statistics in Medicine 2008; 27:333–342.
28. Meeting materials for the January 16, 2014 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Food and Drug Administration website. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm378911.htm. Updated July 28, 2014. Accessed August 25, 2014.